Preclinical in vitro and in vivo pharmacokinetic properties of danicamtiv, a new targeted myosin activator for the treatment of dilated cardiomyopathy
| Autor: | Mark P. Grillo, Svetlana Markova, Marc Evanchik, Marc Trellu, Patricia Moliner, Priscilla Brun, Anne Perreard-Dumaine, Pascale Vicat, Chun Yang, James P. Driscoll, Tim J. Carlson |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Health Toxicology and Mutagenesis Toxicology Left ventricular enlargement 030226 pharmacology & pharmacy Biochemistry 03 medical and health sciences 0302 clinical medicine Pharmacokinetics In vivo Internal medicine Myosin medicine cardiovascular diseases Pharmacology business.industry Activator (genetics) Dilated cardiomyopathy General Medicine medicine.disease In vitro 030220 oncology & carcinogenesis Heart failure cardiovascular system Cardiology business |
| Zdroj: | Xenobiotica. 51:222-238 |
| ISSN: | 1366-5928 0049-8254 |
| Popis: | Dilated cardiomyopathy (DCM) is a disease of the myocardium defined by left ventricular enlargement and systolic dysfunction leading to heart failure. Danicamtiv, a new targeted myosin activator de... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|